CTOs on the Move

Memometal

www.mmi-usa.com

 
Memometal is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 10K-50K
  • Annual Revenue: $1-10 Million
  • www.mmi-usa.com
  • 6060 Poplar Ave
    Memphis, TN USA 38119
  • Phone: 901.685.7557

Executives

Name Title Contact Details

Similar Companies

Cedar Community Foundation

Cedar Community Foundation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in West Bend, WI. To find more information about Cedar Community Foundation, please visit www.cedarcommunity.org

Netwal Dental Laboratory Inc

Netwal Dental Laboratory Inc is a La Crosse, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lawndale Christian Health Center

Lawndale Christian Health Center is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Astra-Lite

Astra-Lite is a Watsonville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Humacyte

Humacyte develops novel human tissue-based investigational products for potential applications in regenerative medicine and vascular surgery. The company uses a proprietary technology platform to isolate and grow stable, “off-the shelf” investigational human tissue replacements that, if approved, could be tailored to pre-designed clinical and commercial specifications. Unique in their construction and composition, Humacyte`s investigational tissues could be grown as large and small diameter tubes for investigational use in vascular surgery, and potentially, as sheets for patching damaged organs and tissues Humacyte`s investigational product candidates are acellular extracellular matrices, which are formed in vitro from banked vascular smooth muscle cells and then decellularized, with the goal of eliminating the risk of rejection. No cells from the patient are required for this production process. The resulting end product is designed to have a significant shelf life for onsite storage at hospitals and if approved, may have the potential to be readily available for patients in need of vascular access or replacement.